Hedskog C, Rodriguez L, Hu Y, Li J, et al. SARS-CoV-2 Resistance Analyses From the Phase 3 BIRCH Study of Obeldesivir in High-Risk Nonhospitalized Participants With COVID-19. Antiviral Res 2026 Jan 19:106351. doi: 10.1016/j.antiviral.2026.106351.
PMID: 41565160